Sai Parenterals MD, chairman, board of directors and AGM
NSE: SAIPARENTBSE: 544742Pharmaceuticals & BiotechnologySmall Cap
Share price at the NSE close on 23 Oct 2026. Previous close ₹451.50.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹2,040 Cr1,118th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit.
- No full year
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 23 May 2026
- 4.2
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonesince listing in Apr 2026
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 23 May 2026
- 0.65
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 3,20,04060.5% delivered
Sai Parenterals board of directors
At the end of the quarter to Jun 2026, as the company filed it; changes since are in its announcements.
- Chairperson and managing directorAnil Kumar Karusala
- Company Secretary and Compliance OfficerShivali Aggarwal
6 directors3 independent2 executive1 non-executive
- Anil Kumar Karusala · Chairperson and managing directorExecutive · joined Nov 2021 · reappointed Jan 2024 · 1 listed board · 1 committee seat
- Vijitha GorrepatiExecutive · joined Aug 2016 · reappointed Jan 2024 · 2 listed boards · 1 as independent · 2 committee seats, 1 as chair
- Aruna KarusalaNon-executive · joined Aug 2016 · 1 listed board
- Seeta Ram Anjaneyulu GorantlaIndependent · joined Jan 2024 · 30 months as independent · 1 listed board · 1 as independent · 2 committee seats, 1 as chair
- Bhagyashri Dharmasa ZadIndependent · joined Jan 2024 · 30 months as independent · 2 listed boards · 2 as independent · 4 committee seats, 1 as chair
- Kalidindi V RajuIndependent · joined Nov 2024 · 19 months as independent · 1 listed board · 1 as independent
An independent director has no business or family tie to the company, its promoters or its managers beyond the seat. Listed boards counts the boards of listed companies the director sits on, this one included, and "as independent" how many of those seats are independent ones. Committee seats are audit and stakeholder committee seats across those companies. Months as independent is filed for independent directors only, whose terms the rules cap. Disqualified is the company's own mark that a director may not serve under company law.
Committees and meetings
Who sits on each, and how often they met.Board meeting notices and outcomes
Board
- 23 May 20266 of 6 present3 independent · 32 days in between
- 20 Apr 20266 of 6 present3 independent · 20 days in between
- 30 Mar 20266 of 6 present3 independent · 1 day in between
- 28 Mar 20266 of 6 present3 independent · no day in between
7 earlier meetings
- 27 Mar 20266 of 6 present3 independent · 3 days in between
- 23 Mar 20266 of 6 present3 independent · 5 days in between
- 17 Mar 20266 of 6 present3 independent · no day in between
- 16 Mar 20266 of 6 present3 independent · 18 days in between
- 25 Feb 20266 of 6 present3 independent · 18 days in between
- 6 Feb 20266 of 6 present3 independent · 3 days in between
- 2 Feb 20266 of 6 present3 independent
Audit Committee
Chair Bhagyashri Dharmasa Zad
Seeta Ram Anjaneyulu Gorantla, Anil Kumar Karusala
- 23 May 20263 of 3 present2 independent · 32 days in between
- 20 Apr 20263 of 3 present2 independent · 62 days in between
- 16 Feb 20263 of 3 present2 independent · 9 days in between
- 6 Feb 20263 of 3 present2 independent · 3 days in between
1 earlier meeting
- 2 Feb 20263 of 3 present2 independent
Nomination and remuneration committee
Chair Bhagyashri Dharmasa Zad
Seeta Ram Anjaneyulu Gorantla, Aruna Karusala
No meeting listed in the filing.
Stakeholders Relationship Committee
Chair Seeta Ram Anjaneyulu Gorantla
Bhagyashri Dharmasa Zad, Aruna Karusala
No meeting listed in the filing.
Corporate Social Responsibility Committee
Chair Seeta Ram Anjaneyulu Gorantla
Vijitha Gorrepati, Anil Kumar Karusala
No meeting listed in the filing.
Meetings in the quarter filed and the one before it. The days in between are as the company files them, neither meeting's day counted; the rules allow at most 120. A quorum is the least number of members who must attend for the meeting to decide anything.
Statutory auditor
Named in the results for the quarter to Mar 2026.
- R Kabra & Co. LLPPeer-review certificate valid to Mar 2029
A statutory auditor checks the company's accounts and signs its results. Peer review is the accountants' institute's check of an audit firm's own work, which a listed company's auditor must hold a valid certificate of.
Sai Parenterals AGM and shareholder votes
Each resolution, how the votes went, and how institutions voted apart from the promoters. A postal ballot is a vote by post or online, held without a meeting.Sai Parenterals share news and announcements
Annual general meeting, 10 Sep 2026
13,883 shareholders on the register on 3 Sep 2026; present: 4 promoters and 50 others; votes counted by Aakanksha Sachin Dubey / Aakanksha Dubey & Co.The company's voting result (opens in a new tab)
To receive, consider and adopt the Audited Balance Sheet as at March 31st, 2026, the Statement of Profit & Loss and Cash Flow Statement, (Standalone and consolidated) for the year ended on that date together with the Notes attached thereto, along with the Reports of Auditors and Directors thereon.MoreLess
Ordinary100.00% for0.00% againstAgainst: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 75.80% · promoters 100.00% · institutions 84.97% · other public 40.68%
- To appoint a director in place of Mr. Anil Kumar Karusala (DIN: 01866646) who retires by rotation and being eligible, offers himself for re-appointment.OrdinaryPromoters have an interest in it100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 75.80% · promoters 100.00% · institutions 84.97% · other public 40.68%
- Re-appointment of Mr. Anil Kumar Karusala (DIN: 01866646) as Managing Director of the company.SpecialPromoters have an interest in it99.99% for0.01% against
Against: promoters 0.00% · institutions 0.00% · other public 0.06%
Turnout: all 75.80% · promoters 100.00% · institutions 84.97% · other public 40.68%
- Re-Appointment Of Mrs. Vijitha Gorrepati (DIN: 03492979) As Whole-Time Director of the company.SpecialPromoters have an interest in it99.99% for0.01% against
Against: promoters 0.00% · institutions 0.00% · other public 0.07%
Turnout: all 75.80% · promoters 100.00% · institutions 84.97% · other public 40.68%
- To appoint Mr. Kunal Kakumanu (DIN:11281388) as an Executive Director of the Company.SpecialPromoters have an interest in it99.91% for0.09% against
Against: promoters 0.00% · institutions 0.61% · other public 0.06%
Turnout: all 75.80% · promoters 100.00% · institutions 84.97% · other public 40.68%
- To appoint M/s. Aakanksha Dubey & Co., Practicing Company Secretaries as secretarial auditors for a term of up to 5 (Five) Consecutive Years.Ordinary99.99% for0.01% against
Against: promoters 0.00% · institutions 0.00% · other public 0.06%
Turnout: all 75.80% · promoters 100.00% · institutions 84.97% · other public 40.69%
Variation in the objects and/or terms of utilisation of the IPO Proceeds and extension of the time period for utilisation of the IPO Proceeds as disclosed in the prospectus dated march 28, 2026, relating to Objects (A) Capacity Expansion and Upgradation of Manufacturing Facilities and (B) Establishment of a Research & Development Centre.MoreLess
Special99.99% for0.01% againstAgainst: promoters 0.00% · institutions 0.00% · other public 0.06%
Turnout: all 75.80% · promoters 100.00% · institutions 84.97% · other public 40.68%
- Ratification of the Sai Parenteral’s Limited Employee Stock Option Plan 2025 (“Esop Scheme - 2025”) of the Company.Special96.81% for3.19% against
Against: promoters 0.00% · institutions 26.31% · other public 0.06%
Turnout: all 75.80% · promoters 100.00% · institutions 84.97% · other public 40.68%
- Ratification of the Extension of Benefits of the Sai Parenteral’s Limited Employee Stock Option Plan 2025 (“Esop Scheme - 2025”) to the Subsidiary Companies.Special96.81% for3.19% against
Against: promoters 0.00% · institutions 26.31% · other public 0.06%
Turnout: all 75.80% · promoters 100.00% · institutions 84.97% · other public 40.68%
To Consider and approve the Material Related Party Transaction of the Company in respect of the Grant of a Loan to Sai Singapore Pte. Ltd. for Downstream funding to Noumed Pharmaceuticals Pty. Limited, Australia.MoreLess
OrdinaryPromoters have an interest in it90.41% for9.59% againstAgainst: promoters 0.00% · institutions 25.70% · other public 0.06%
Turnout: all 24.65% · promoters 0.00% · institutions 84.97% · other public 40.68%
- To approve Material Related Party Transactions of the Company with Noumed Pharmaceuticals Pty. Limited, Step-Down Subsidiary Company for the FY 2026-27.OrdinaryPromoters have an interest in it99.96% for0.04% against
Against: promoters 0.00% · institutions 0.00% · other public 0.06%
Turnout: all 24.65% · promoters 0.00% · institutions 84.97% · other public 40.68%
- Ratification of Payment of Remuneration to the Cost Auditor for the Financial Year 2026-27.Ordinary99.99% for0.01% against
Against: promoters 0.00% · institutions 0.00% · other public 0.06%
Turnout: all 75.80% · promoters 100.00% · institutions 84.97% · other public 40.68%
For and against are per cent of the votes cast. Turnout is the votes cast as a per cent of the shares each group holds. Institutions are funds, insurers, banks and foreign investors. An ordinary resolution passes with more than half the votes cast, a special one with at least three quarters.
Fines and tax disputes
Reported in the filing for the quarter to Jun 2026.
- Fine or penaltyBSE LimitedSince 30 Jun 2026
SOP Fine of Rs.1,77,000/- which has been paid by the company
Late submission of Financial Results for December 2025 Quarter - Tax disputeAdditional / Joint Commissioner, Central Tax, Appeals - II, 7th floor, GST Bhavan, Basheerbagh, HyderabadSince 22 Jul 2025Appeal Order issued
- Tax disputeIncome Tax Department, Circle 3(1), IT Tower, HyderabadSince 16 Mar 2023Hearing Stage
- Tax disputeIncome Tax Department, Circle 3(1), IT Tower, HyderabadSince 10 Apr 2025Hearing Stage
- Tax disputeIncome Tax Department, Circle 3(1), IT Tower, HyderabadSince 11 Dec 2024Hearing Stage
In the company's own words, from its latest governance filing.
Investor complaints and compliance
Quarter by quarter.
Investor complaints received and resolved, the company's own count
- Received
- Resolved
Open at the quarter's end
- The board is made up as the listing rules require
- Yes
- The board has a regular chairperson
- Yes
- The company has a risk management committee
- No
- The chair is related to the managing director
- No
- The filing has a part on fines and penalties
- Yes
- The filing has a part on tax disputes
- Yes
- There was a cyber security incident in the quarter
- No
The company's own answers in its filing.
How money raised was used
Reported for the quarter to Jun 2026.
| Raised | Amount raised | For | Set aside | Spent | Spent elsewhere |
|---|---|---|---|---|---|
| Public IssuesMar 2026, checked by India Ratings & Research Private Limited | 285.00 | Capacity expansion and upgradation of manufacturing facilities | 110.80 | 6.81 | No |
| Public IssuesMar 2026, checked by India Ratings & Research Private Limited | 285.00 | Establishment of a new R&D Centre | 18.02 | 0.00 | No |
| Public IssuesMar 2026, checked by India Ratings & Research Private Limited | 285.00 | Repayment / p-repayment- of certain outstanding borrowings | 14.30 | 13.65 | No |
| Public IssuesMar 2026, checked by India Ratings & Research Private Limited | 285.00 | Working capital requirements | 33.00 | 33.00 | No |
| Public IssuesMar 2026, checked by India Ratings & Research Private Limited | 285.00 | Repayment of bridge loan and term loan availed for investment in wholly owned subsidiary, Sai Parenterals Pte Limited (Singapore), in relation to the acquisition of Noumed Pharmaceuticals Pty Limited (Australia) | 35.64 | 35.64 | No |
| Public IssuesMar 2026, checked by India Ratings & Research Private Limited | 285.00 | General Corporate Purposes | 44.74 | 18.99 | No |
| Public IssuesMar 2026, checked by India Ratings & Research Private Limited | 285.00 | Issue Related Expenses | 28.50 | 28.50 | No |